Black Diamond Therapeutics discontinues BDTX-189, cuts workforce 30% to extend cash runway into Q3 2024

Black Diamond Therapeutics, Inc.

Discontinued BDTX-189 due to rapid evolution of NSCLC treatment landscape (EGFR/HER2 Exon 20 insertions).
Reduced workforce by ~30% to increase operational efficiency and extend cash runway.
Cash runway extended into Q3 2024; $209M in cash, equivalents, and investments as of Dec 31, 2021.
Prioritized BDTX-1535 (Phase 1 for GBM/NSCLC) with clinical data update expected in 2023.
Prioritized BDTX-4933 (BRAF inhibitor); IND submission expected in first half of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.